These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
667 related items for PubMed ID: 18197181
21. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. Roldán V, Marín F, Gimeno JR, Ruiz-Espejo F, González J, Feliu E, García-Honrubia A, Saura D, de la Morena G, Valdés M, Vicente V. Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501 [Abstract] [Full Text] [Related]
22. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure]. Yang YJ, Zhang X, Zhu WL, Huang Y. Zhonghua Yi Xue Za Zhi; 2006 Jun 27; 86(24):1693-6. PubMed ID: 16854324 [Abstract] [Full Text] [Related]
24. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function. Orn S, Manhenke C, Squire IB, Ng L, Anand I, Dickstein K. J Card Fail; 2007 Dec 27; 13(10):843-9. PubMed ID: 18068618 [Abstract] [Full Text] [Related]
25. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Palei AC, Sandrim VC, Cavalli RC, Tanus-Santos JE. Clin Biochem; 2008 Jul 27; 41(10-11):875-80. PubMed ID: 18477480 [Abstract] [Full Text] [Related]
26. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, Clark LL, Stroud RE, Corn WC, Finklea L, Zile MR, Spinale FG. Circulation; 2006 Sep 05; 114(10):1020-7. PubMed ID: 16923753 [Abstract] [Full Text] [Related]
28. Imbalance of metallaproteinase/tissue inhibitors of metalloproteinase system in renal transplant recipients with chronic allograft injury. Mazanowska O, Kamińska D, Krajewska M, Zabińska M, Kopeć W, Boratyńska M, Chudoba P, Patrzalek D, Klinger M. Transplant Proc; 2011 Oct 05; 43(8):3000-3. PubMed ID: 21996210 [Abstract] [Full Text] [Related]
29. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Määtta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M. Anticancer Res; 2007 Oct 05; 27(4C):2753-8. PubMed ID: 17695443 [Abstract] [Full Text] [Related]
32. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction. Yasuda S, Miyazaki S, Kinoshita H, Nagaya N, Kanda M, Goto Y, Nonogi H. Clin Sci (Lond); 2007 Jan 05; 112(1):43-9. PubMed ID: 16939410 [Abstract] [Full Text] [Related]